HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a price target of $23.
July 03, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences and maintained a price target of $23, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $23 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. It suggests confidence in Tyra Biosciences' future performance and could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100